Ethereum Rises But Remains Below This Key Level; Maker Emerges As Top Gainer

Bitcoin (CRYPTO: BTC) traded higher, with the cryptocurrency prices trading close to the $26,300 level on Tuesday. Ethereum (CRYPTO: ETH) also moved higher, but traded below the key $1,600 mark this morning.

Bitcoin (CRYPTO: BTC) traded higher, with the cryptocurrency prices trading close to the $26,300 level on Tuesday.

Ethereum (CRYPTO: ETH) also moved higher, but traded below the key $1,600 mark this morning.

Maker (CRYPTO: MKR) was the top gainer over the prior 24 hours, while Render (CRYPTO: RNDR) turned out to be the biggest loser.

At the time of writing, the global crypto market cap rose to $1.05 trillion, recording a 24-hour gain of 0.5%. BTC was trading higher by 0.9% at $26,295 while ETH rose by around 1.3% to $1,595 on Tuesday.

Here are the top ten crypto gainers and losers over the past 24 hours:

Gainers

Maker (CRYPTO: MKR)
Price: $1,335.50
24-hour gain: 4.8%

Frax Share (CRYPTO: FXS)
Price: $5.70
24-hour gain: 3.2%

GMX (CRYPTO: GMX)
Price: $34.96
24-hour gain: 3.2%

Bitcoin Cash (CRYPTO: BCH)
Price: $212.99
24-hour gain: 3.1%

Chainlink (CRYPTO: LINK)
Price: $7.44
24-hour gain: 2.7%

Losers

Render (CRYPTO: RNDR)
Price: $1.49
24-hour drop: 3.6%

Quant (CRYPTO: QNT)
Price: $85.92
24-hour drop: 3.3%

Aptos (CRYPTO: APT)
Price: $5.46
24-hour drop: 3.1%

Compound (CRYPTO: COMP)
Price: $39.38
24-hour drop: 2.8%

Immutable (CRYPTO: IMX)
Price: $0.5897
24-hour drop: 2.6%

Read This Next: TD SYNNEX, Profound Medical And 3 Stocks To Watch Heading Into Tuesday

Total
0
Shares
Related Posts
Read More

Novartis Confirmed That It Has Been Contacted by the Swiss Competition Commission Regarding an Investigation Into the Assertion of a Patent Related to Dermatology Treatments

Novartis today confirms that it has been contacted by the Swiss Competition Commission (COMCO) which has initiated an investigation, in collaboration with the European Commission, into the assertion of a patent in the broader field of dermatology treatments. In connection with this investigation, COMCO representatives visited the company headquarters in Basel.

NVS

Read More

Reported Late Tuesday, AdaptHealth Provides FY23 Guidance And Preliminary Commentary On Q4 2022 Results; Sees FY23 Revenue $3.21B-$3.29B; Adj. EBITDA $690M-$750M; Sees FY22 Revenue To Be Near Midpoint Of Previous Guidance Of $2.95B-$3.01B

AdaptHealth Corp. (NASDAQ:AHCO) ("AdaptHealth" or the "Company"), a national leader in providing patient-centered, healthcare-at-home solutions, including home medical equipment, medical supplies and

AHCO